MoNd nano material for treating polycystic ovarian syndrome and application of MoNd nano material
By preparing MoNd nanoclusters, the shortcomings of polycystic ovary syndrome treatment in the prior art were solved, and efficiently and safely alleviated PCOS-related oxidative stress and inflammatory responses were achieved, normal follicle development, and improved ovulation and pregnancy rates.
Patent Information
- Application Number
- CN202510592091.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2025-08-01
AI Technical Summary
The prior art lacks effective methods for treating polycystic ovary syndrome (PCOS), especially in relieving inflammation and oxidative stress.
MoNd nanoclusters were synthesized by a simple one-pot method to prepare neodymium modified molybdenum blue nanomaterials. MoNd and neodymium were uniformly distributed in the MoNd nanoclusters. There was a polyvalent combination of Mo5+ and Mo6+ in the Mo3d orbit, while the Nd3d energy spectrum was only manifested as a characteristic peak of Nd3+, with excellent ROS neutralization activity and anti-inflammatory properties.
MoNd nanoclusters significantly reduce cytotoxicity, have powerful ROS clearance and anti-inflammatory properties, can improve the ovarian microenvironment, restore normal follicle development, improve ovulation and pregnancy rates, and improve PCOS-related symptoms.
Smart Images
Figure CN120392808A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical biotechnology, and more particularly, to a MoNd nanomaterial for treating polycystic ovary syndrome and its applications. Background Art
[0002] Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. Its main characteristics include hyperandrogenism, irregular menstruation, and the presence of polycystic ovaries. The disease is often associated with metabolic disorders, including obesity and insulin resistance. Although the pathogenesis of PCOS involves multiple genetic and other factors, there is still a lack of effective therapeutic targets and biotherapies, highlighting the urgent need to develop novel and more effective treatment strategies.
[0003] The clinical manifestations of PCOS are closely related to systemic inflammation and oxidative stress, both of which play important roles in the pathogenesis of the disease. Chronic low-grade inflammation is a recognized feature of PCOS, and increasing evidence suggests that the inflammatory microenvironment within the ovary exacerbates abnormal follicular development, potentially leading to anovulation and infertility. At the same time, oxidative stress - a pathological state caused by the overproduction of reactive oxygen species (ROS) and the imbalance of the antioxidant defense system - is also considered one of the important factors in the occurrence and development of PCOS.
[0004] Polyoxometalates (POMs) are a class of special molecular clusters composed of one or more transition metal elements and oxygen atoms. Due to their diverse elemental composition and rich structural variations, POMs have shown broad application prospects in the fields of catalysis, materials science, and biomedicine. In particular, molybdenum-based POMs, such as molybdenum blue (MB), often exhibit delicate wheel-like structures and have received high attention in recent years due to their potential in the treatment of tumors and inflammatory diseases. For example, the classic tetradecameric {Mo154} structure has a delicate wheel-like configuration composed of {Mo8} main building units based on pentagonal structures and is constructed through {Mo2} and {Mo1} linking units. {Mo154} has excellent free radical scavenging ability, which is attributed to the multivalent redox properties of molybdenum. In addition, its good water solubility further highlights its application potential in systemic therapy. However, due to its significant cytotoxicity, the clinical translation of {Mo154} in the treatment of ROS-related inflammatory diseases is limited.
[0005] In recent years, rare earth-based nanomaterials have shown great potential in the biomedical field. In particular, nanostructures doped with neodymium (Nd) have attracted attention due to their unique optical and magnetic properties, which stem from the unique electronic configuration of Nd. Meanwhile, Nd-doped structures also exhibit ideal biocompatibility, providing more possibilities for their biomedical applications. The latest research proposes that by precisely replacing the {Mo2} linking units in the {Mo154} wheel-like structure with the rare earth element Nd 3 + ions, it is possible to optimize the structure without changing the multi-valent redox properties of Mo, and theoretically retain its function of scavenging ROS.
[0006] In this study, we successfully prepared neodymium-modified molybdenum blue (MoNd) nanoclusters through a simple one-pot synthesis strategy, achieving controllable doping of Nd in the {Mo154} macrocyclic structure. The obtained MoNd nanoclusters not only showed stronger ROS neutralization activity compared to the original {Mo154}, but also maintained good water solubility and significantly reduced cytotoxicity. This structural regulation strategy demonstrates the feasibility of optimizing POM-based nano-therapeutics through rare earth doping, taking into account both their biological activity and biocompatibility, and providing new ideas for the treatment of inflammatory diseases. Our research found that MoNd not only has excellent biosafety, but can also effectively relieve PCOS symptoms through potent ROS scavenging and anti-inflammatory properties. This study supports the application prospect of MoNd as a highly efficient PCOS nano-therapeutic agent with disease repair potential, shows its potential in future clinical translation, and opens up a new path for the nano-material intervention treatment of PCOS. Summary of the Invention
[0007] The first object of the present invention is to provide a MoNd nanomaterial for treating polycystic ovary syndrome in view of the deficiencies in the prior art.
[0008] The second object of the present invention is a preparation method of the MoNd nanomaterial.
[0009] The third object of the present invention is the use of the MoNd nanomaterial.
[0010] To achieve the above first object, the technical solution adopted by the present invention is: a MoNd nanomaterial for treating polycystic ovary syndrome, the MoNd nanomaterial is synthesized by a one-pot reaction to form neodymium-modified MoNd nanoclusters, and molybdenum and neodymium are uniformly distributed in the MoNd nanoclusters, and there are multi-valent combinations of Mo 5+ and Mo 6+ in the Mo3d orbit, while the Nd3d energy spectrum only shows the characteristic peak of Nd 3+
[0011] As a preferred example, the MoNd nanomaterial is prepared by the following method: Neodymium(III) chloride hexahydrate and hydrazine hydrochloride are dissolved in water, and then hydrochloric acid is added dropwise. Na2MoO4·2H2O dissolved in water is added to the above mixed system.
[0012] As a preferred example, when the pH value of the reaction system is stabilized at 1.8, stirring is continued at room temperature, and the solution gradually turns into a clear blue color. Subsequently, the obtained solution is transferred to a glass bottle with a metal cap and a rubber diaphragm. The diaphragm is pierced with a needle, and then the bottle is placed in an oven and reacted at 100 °C for 4 days.
[0013] As a preferred example, 20 mg of neodymium(III) chloride hexahydrate and 3 mg of hydrazine hydrochloride are dissolved in 4.5 mL of water, and then 0.4 mL of 1 M hydrochloric acid is slowly added dropwise under stirring. 50 mg of Na2MoO4·2H2O is dissolved in 0.5 mL of water and added to the above mixed system.
[0014] To achieve the above second object, the technical solution adopted by the present invention is: A method for preparing a MoNd nanomaterial for treating polycystic ovary syndrome: The method for preparing the MoNd nanomaterial includes the following steps: Neodymium(III) chloride hexahydrate and hydrazine hydrochloride are dissolved in water, and then hydrochloric acid is added dropwise. Na2MoO4·2H2O dissolved in water is added to the above mixed system.
[0015] As a preferred example, when the pH value of the reaction system is stabilized at 1.8, stirring is continued at room temperature for minutes, and the solution gradually turns into a clear blue color. Subsequently, the obtained solution is transferred to a glass bottle with a metal cap and a rubber diaphragm. The diaphragm is pierced with a needle, and then the bottle is placed in an oven and reacted at 100 °C for 4 days.
[0016] As a preferred example, 20 mg of neodymium(III) chloride hexahydrate and 3 mg of hydrazine hydrochloride are dissolved in 4.5 mL of water, and then 0.4 mL of 1 M hydrochloric acid is slowly added dropwise under stirring. 50 mg of Na2MoO4·2H2O is dissolved in 0.5 mL of water and added to the above mixed system.
[0017] To achieve the above third object, the technical solution adopted by the present invention is: The application of the MoNd nanomaterial in the preparation of a drug for treating polycystic ovary syndrome.
[0018] As a preferred example, the application of the MoNd nanomaterial in the preparation of a drug for improving the metabolic function of polycystic ovary syndrome.
[0019] The advantages of the present invention are as follows: MoNd nanoclusters have excellent reactive oxygen species (ROS) scavenging ability and good biocompatibility, and can effectively alleviate oxidative stress and inflammatory responses related to polycystic ovary syndrome (PCOS). The present invention first introduces the rare earth element Nd into the polyoxometalate structure to prepare a MoNd nanomaterial with stable structure and optimized functions, and confirms its good antioxidant and immunomodulatory functions in vivo. MoNd can improve the ovarian microenvironment, restore the function of granulosa cells, promote normal follicular development, and thus increase the ovulation rate and pregnancy rate.
[0020] At present, the treatment methods for PCOS are still relatively limited, especially lacking efficient and safe intervention means in alleviating inflammation and oxidative stress. The present invention provides a new material intervention strategy for the treatment of PCOS, and is expected to develop into a safe, efficient and highly targeted nanodrug, filling the technical gap in this field and promoting the diversification and precision of PCOS treatment methods.
[0021] From the perspective of social benefits, this invention helps to improve women's fertility, reduce complications such as infertility and metabolic syndrome caused by PCOS, and improve women's quality of life. From the economic benefit perspective, the development and industrialization of MoNd nanodrugs will bring new market growth points to the fields of reproductive health and gynecological treatment, have broad application prospects and commercial value, and promote the development of related industries of nanomedicine and women's health in China. Brief Description of the Drawings
[0022] Figure 1 : EDX spectral analysis and EDX elemental mapping images of MoNd nanoclusters.
[0023] Figure 2 : X-ray photoelectron spectroscopy (XPS) analysis.
[0024] Figure 3 : Determination of free radical scavenging ability by ABTS·+ method.
[0025] Figure 4 : Determination of free radical scavenging ability by DPPH· method.
[0026] Figure 5 : Biosafety assessment of ovarian granulosa cell line treated with MoNd.
[0027] Figure 6 : Determination of the ability to scavenge reactive oxygen species after treating ovarian granulosa cell line with MoNd.
[0028] Figure 7 : MoNd treatment improved the polycystic ovary phenotype in PCOS mice. Detailed Description of the Invention
[0029] Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiments are only used to illustrate the present invention and are not used in limiting the scope of the present invention.In addition, should be understood that after reading the content of the present invention record, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall equally within the scope limited by the application's appended claims.
[0030] Example 1 Synthesis and Characterization of MoNd Nanoclusters
[0031] Neodymium-modified molybdenum blue (MoNd) nanoclusters were synthesized via a simplified one-pot reaction. Specifically, 20 mg of neodymium chloride hexahydrate (NdCl3·6H2O) and 3 mg of hydrazine hydrochloride were dissolved in 4.5 mL of water. 0.4 mL of 1 M hydrochloric acid was then slowly added dropwise while stirring. Prior to this, 50 mg of Na2MoO4·2H2O was dissolved in 0.5 mL of water and added to the mixture. When the pH of the reaction stabilized at 1.8, stirring was continued at room temperature (25°C) for 10 minutes, during which the solution gradually turned clear blue. The resulting solution was then transferred to a 20 mL metal-capped glass vial with a rubber septum. The septum was pierced with a 1.2 mm inner diameter needle. The vial was then placed in an oven at 100°C for 4 days. A dark blue MoNd solution was obtained, which was freeze-dried and stored for future studies. The chemical reagents used included NdCl3·6H2O, hydrazine hydrochloride, and hydrochloric acid, all purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. The morphology and composition of MoNd were analyzed by energy dispersive element mapping (EDX). The element distribution map of energy dispersive element analysis confirmed the uniform distribution of molybdenum (Mo) and neodymium (Nd) in the MoNd nanoclusters, indicating that Nd 3+ Successfully and evenly replaced some components in the {Mo2} bonding unit ( Figure 1 ). Thermo ESCALAB 250XI X-ray photoelectron spectrometer (XPS) was used to analyze the valence information of Mo and Nd elements. X-ray photoelectron spectroscopy (XPS) analysis showed that there was Mo in the Mo 3d orbital. 5+ and Mo 6+ The multi-valence combination of Nd 3d spectrum only shows Nd 3+ The mixed valence structure of molybdenum indicates that MoNd nanoclusters have good redox activity and also provide a potential mechanism for their free radical scavenging ability ( Figure 2 ).
[0032] Example 2 Evaluation of free radical scavenging ability of MoNd nanoclusters
[0033] The free radical scavenging ability of MoNd nanoclusters was evaluated by various methods. Typical antioxidant activity assays were performed, including ABTS·+ ABTS(2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) and DPPH (2,2-diphenyl-1-picrylhydrazyl) experiments. Both ABTS and DPPH were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0034] In the ABTS· + experiment ( Figure 3 ), 0.2 mL of ABTS solution (7.4 mmol / L) was mixed with 0.2 mL of potassium persulfate solution (2.6 mmol / L), and the reaction was carried out for 24 hours under dark conditions to generate ABTS· + . The resulting solution was diluted 50 times with PBS buffer and used to react with MoNd nanoclusters. Subsequently, 0.6 mL of MoNd solutions with different concentrations was mixed with 2.4 mL of ABTS· + solution. After reacting for 10 minutes, the absorbance was measured at a wavelength of 734 nm using a UV-visible spectrophotometer (UV-vis). The UV-visible absorption spectrum was measured by a UV-1900i UV-visible spectrophotometer. Each group of measurements was repeated three times for quantitative analysis. The scavenging rate (inhibition rate) of free radicals was calculated according to the following formula:
[0035]
[0036] where A0 represents the absorbance value before adding MoNd nanoclusters, and A represents the absorbance value after the reaction. We can see that the absorbance decreased significantly at 734 nm.
[0037] In the DPPH· experiment ( Figure 4 ), a DPPH ethanol solution with a concentration of 0.04 mg / mL was prepared in advance. Then, 2 mL of MoNd solutions with different concentrations was mixed with 2 mL of DPPH solution. After reacting for 30 minutes, the absorbance was measured at 519 nm (using a UV-vis spectrophotometer, and the calculation method is the same as above). We can see that the absorbance decreased when observed at 519 nm.
[0038] The decrease in absorbance in the ABTS·+ and DPPH· assays represents the degree of free radical scavenging (or reduction), which is an indication of the antioxidant activity of the MoNd nanoclusters. The ABTS·+ and DPPH· free radicals themselves have specific colors (green and purple, respectively) and strong absorption at 734 nm (ABTS·+) and 519 nm (DPPH·) under ultraviolet-visible light. When antioxidant materials such as MoNd are present, they react with these free radicals, neutralize or reduce them, resulting in a decrease in the number of free radicals and a lighter color. As a result, the absorbance at the corresponding wavelength decreases, indicating that the free radicals are scavenged and reflecting the free radical scavenging ability of the material. Therefore, the more obvious the decrease in absorbance, the more free radicals are scavenged, which means the stronger the antioxidant ability of the tested material.
[0039] In this study, the results showed that in the DPPH · and ABTS ·+ assays, a significant decrease in absorption intensity was observed at 724 nm and 519 nm, respectively, indicating that the MoNd nanoclusters have strong free radical scavenging ability.
[0040] Example 3 Biosafety assessment of MoNd-treated ovarian granulosa cell line and determination of reactive oxygen species scavenging ability
[0041] We used the ovarian granulosa cell line KGN to evaluate the biosafety of MoNd and to determine its ability to scavenge reactive oxygen species. We used the Cell Counting Kit-8 (CCK8) assay to detect and evaluate cell viability. Cells were seeded in 96-well plates at a density of approximately 2000 cells per well. To avoid affecting cell attachment, MoNd was not added at the initial stage. After 6 hours, the cells had successfully attached, and the initial cell viability was evaluated using the CCK-8 kit. The test method was to add 10 μL of CCK-8 reagent to each well and continue to incubate at 37 °C and 5% CO2 for 2 hours. The absorbance values of each well were measured at a wavelength of 450 nm using a microplate reader. Cell viability was expressed as the ratio of the absorbance of the treatment group to that of the control group, and the control group was normalized as 100% viability. The test results at 6 h showed no significant difference in cell viability among the groups, indicating that the initial seeding density was consistent among the groups. Subsequently, different concentrations of MoNd (0, 10, 20, 50, and 100 μg / mL) were added according to the experimental design, and cell viability was detected at 24 hours. Subsequently, KGN cells were treated with different concentrations of MoNd nanoclusters and cell viability was detected after 24 hours. The results showed that there was no significant difference in cell viability among the groups, indicating that the MoNd nanoclusters had little cytotoxicity to granulosa cells ( Figure 5 ). (Note: ns, not significant, no statistical difference).
[0042] Next, we used flow cytometry to evaluate the level of intracellular reactive oxygen species (ROS). KGN cells from different treatment groups were collected, and the intracellular ROS level was detected using a ROS detection kit (S0033, Beyotime, China) provided by Beyotime. The experiment was carried out according to the kit instructions. The brief steps were as follows: The cells were washed twice with PBS to remove the culture medium, and then a working solution of DCFH-DA with a final concentration of 10 μM was added. The cells were incubated at 37 °C for 30 minutes, avoiding light during the incubation. After DCFH-DA entered the cells, it was hydrolyzed by intracellular esterase to non-fluorescent DCFH, which was oxidized to generate green fluorescent DCF under the action of reactive oxygen species. After the incubation, the cells were washed 2–3 times with PBS to remove the probes that did not enter the cells. Subsequently, the cells were collected and resuspended in PBS, and then detected using a flow cytometer. The fluorescence signal of DCF was detected in the FITC channel (excitation wavelength 488 nm, emission wavelength 525 nm). Finally, the fluorescence intensity was analyzed using FlowJo software (or corresponding analysis software) to evaluate the changes in the ROS level in each group of cells. In this study, it was found that after treatment with H2O2, the intracellular ROS level increased significantly, verifying the successful establishment of the oxidative stress model. However, treatment with MoNd nanoclusters significantly reduced the ROS level, further supporting its protective effect in alleviating granulosa cell oxidative stress ( Figure 6 ).
[0043] Example 4 MoNd treatment improved the polycystic ovary phenotype in PCOS mice
[0044] After a 7-day acclimation period to ensure full adaptation to the environment, the experiment was officially started on 3-week-old C57BL / 6J female mice. The experimental mice were randomly divided into three groups. The normal control group (NC group) received subcutaneous injection of sesame oil daily; the PCOS model group received subcutaneous injection of dehydroepiandrosterone (DHEA) at a dose of 6 mg / 100 g body weight (dissolved in sesame oil) daily; the MoNd treatment group received intraperitoneal injection of MoNd nanoclusters (0.5 mg / kg, dissolved in normal saline) in addition to daily DHEA injection. The above treatments were continued for 21 days to establish an animal model, and blood samples and ovarian tissue samples of the three groups of mice were obtained at the end. The PCOS mouse model is typically characterized by cystic follicle formation and hormonal imbalance. Therefore, we performed HE staining on the ovarian tissues of the mice in the NC group, PCOS group, and MoNd group: The ovarian tissues of the mice were fixed with 4% paraformaldehyde for 24 hours, and then dehydrated step by step in 70%, 80%, 90%, 95%, and 100% gradient ethanol for 15 - 30 minutes at each level; then, the tissues were cleared twice with xylene for 10 - 15 minutes each; then, the tissues were embedded in paraffin to prepare paraffin-embedded blocks. The paraffin blocks were sectioned to a thickness of 5 μm with a paraffin slicer, attached to glass slides, and baked at 60°C for 1 hour for standby. After dewaxing, the sections were dewaxed successively with xylene I and II (10 minutes each), and then rehydrated successively in 100%, 95%, 90%, 80%, and 70% ethanol gradients for 5 minutes at each level, and finally rinsed with distilled water. Then, the sections were stained with hematoxylin solution for 5 - 10 minutes, taken out and rinsed with tap water, then differentiated with 1% hydrochloric acid alcohol for a few seconds, and immediately rinsed with running water for "blue return" for 10 minutes. Then, the sections were placed in eosin staining solution for 1 - 3 minutes and quickly rinsed with distilled water. After staining, the sections were dehydrated successively in 70%, 80%, 90%, 95%, and 100% ethanol for 5 minutes at each level, and then placed in xylene for clearing twice for 10 minutes each. Finally, the sections were sealed with neutral gum, air-dried, and the ovarian tissue structure, including histological changes such as follicle morphology and corpus luteum, was observed under a microscope. We performed histopathological evaluation on the ovarian tissues of the three groups of experimental mice, and the results showed that the mice in the PCOS model group showed a higher proportion of cystic follicles, and at the same time, the formation of corpus luteum was significantly reduced. In contrast, follicles at various developmental stages were visible in the ovaries of the control group (NC) and MoNd treatment group mice, and the number of corpus luteum was close to the normal physiological state ( Figure 7A and B). Next, we used enzyme-linked immunosorbent assay (ELISA) to quantitatively detect the testosterone content in the serum of the three groups of mice. We used the kit provided by Abnova (Testosterone ELISA Kit, KA6128) and strictly followed the instructions of the kit. All reagents and samples were restored to room temperature before the experiment. The standard and serum samples were added to the wells of the enzyme-labeled plate, incubated with the HRP enzyme conjugate, and then the plate was washed to remove the unbound components, and the substrate solution was added for color development. After terminating the reaction, the absorbance value (OD) was read with a microplate reader, and the testosterone concentration in each sample was calculated according to the standard curve. We found that compared with the NC group, the serum testosterone level of PCOS model mice was significantly increased, and MoNd treatment could effectively restore the testosterone level to the normal range ( Figure 7 C). In addition, we monitored the body weight of the three groups of mice during the modeling process and found that the body weight of PCOS mice increased significantly compared to the NC group, suggesting metabolic disorders, while the body weight of mice decreased significantly after MoNd intervention, suggesting improved metabolic function ( Figure 7 D). (Note: ***p<0.001, ###p<0.001, statistically significant. In Figure D, *** represents the PCOS group vs. the NC group, and ### represents the MoNd group vs. the PCOS group).
[0045] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.
Claims
1. A MoNd nanomaterial for treating polycystic ovary syndrome, characterized in that, The MoNd nanomaterial is synthesized by a one-pot reaction to form neodymium-modified MoNd nanoclusters. In the MoNd nanoclusters, molybdenum and neodymium are evenly distributed, and there are multiple valence state combinations of Mo 5+ and Mo 6+ in the Mo 3d orbital, while the Nd 3d energy spectrum only shows characteristic peaks of Nd 3+ .
2. The MoNd nanomaterial according to claim 1, characterized in that, The MoNd nanomaterial is prepared by the following method: Neodymium(III) chloride hexahydrate and hydrazine hydrate are dissolved in water, and then hydrochloric acid is added dropwise. Na2MoO4·2H2O dissolved in water is added to the above mixed system.
3. The MoNd nanomaterial according to claim 2, wherein When the pH value of the reaction system is stabilized at 1.8, stirring is continued at room temperature, and the solution gradually turns into a clear blue. Subsequently, the obtained solution is transferred to a glass bottle with a metal cap and a rubber diaphragm. The diaphragm is pierced with a needle, and then the bottle is placed in an oven and reacted at 100 °C for 4 days.
4. The MoNd nanomaterial according to claim 2, wherein 20 mg of neodymium(III) chloride hexahydrate and 3 mg of hydrazine hydrate are dissolved in 4.5 mL of water, and then 0.4 mL of 1 M hydrochloric acid is slowly added dropwise under stirring. 50 mg of Na2MoO4·2H2O is dissolved in 0.5 mL of water and added to the above mixed system.
5. Preparation method of MoNd nanomaterial for treating polycystic ovary syndrome: It is characterized in that, The method for preparing the MoNd nanomaterial comprises the following steps: Neodymium(III) chloride hexahydrate and hydrazine hydrate are dissolved in water, and then hydrochloric acid is added dropwise. Na2MoO4·2H2O dissolved in water is added to the above mixed system.
6. The preparation method of the MoNd nanomaterial according to claim 5, wherein, When the pH value of the reaction system is stabilized at 1.8, stirring is continued at room temperature for minutes, and the solution gradually turns into a clear blue. Subsequently, the obtained solution is transferred to a glass bottle with a metal cap and a rubber diaphragm. The diaphragm is pierced with a needle, and then the bottle is placed in an oven and reacted at 100 °C for 4 days.
7. The preparation method of the MoNd nanomaterial according to claim 5, characterized in that, 20 mg of neodymium(III) chloride hexahydrate and 3 mg of hydrazine hydrate are dissolved in 4.5 mL of water, and then 0.4 mL of 1 M hydrochloric acid is slowly added dropwise under stirring. 50 mg of Na2MoO4·2H2O is dissolved in 0.5 mL of water and added to the above mixed system.
8. Use of the MoNd nanomaterial according to any one of claims 1 - 4 in the preparation of a drug for treating polycystic ovary syndrome.
9. The application according to claim 8, characterized in that, Use of the described MoNd nanomaterial in the preparation of a drug for improving the metabolic function of polycystic ovary syndrome.